Stable aqueous etanercept composition
The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
1. A stable aqueous pharmaceutical composition comprising
an aqueous carrier;
about 50 mg/mL etanercept, about 1% (w/v) sucrose, 0.26% (w/v) to 2% (w/v) mannitol or lysine; the aqueous carrier comprises a buffer, the composition is free of arginine and cysteine, the composition has a pH of about 6.0 to about 6.6, the composition has at least 90 wt. % correctly folded etanercept, the composition has less than 1 wt. % aggregates of etanercept, and
has at M 3 or T 2 or T 4 no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 μm, and
wherein said composition contains less than 50 mM NaCl, and the combination of said sucrose and said mannitol or lysine stabilizes said etanercept in said stable aqueous pharmaceutical composition, wherein the composition has an osmolality from about 180 to about 420 mOsM, and wherein the etanercept is prepared by a mixed mode cation exchange chromatography and mixed mode anion exchange chromatography method resulting in less than 1 wt. % aggregates of etanercept.
2. The stable aqueous pharmaceutical composition of claim 1 , comprising about 10 mM to about 200 mM of the buffer.
3. The stable aqueous composition of claim 1 , comprising about 1 mM to about 30 mM sodium phosphate.
4. The stable aqueous pharmaceutical composition of claim 1 , eliciting long term storage stability as characterized by at least one of:
SEC analysis at M 3 or T 4 at 40° C. of: monomer content greater than 90 wt. %; aggregate content of less than 1 wt. %; and fragment 3 content less than 5 wt. %; and HIC analysis at M 3 or T 2 or T 4 wherein the amount of the composition represented by peak 1 of the HIC chromatogram is less than about 3 wt. %.
5. The stable aqueous pharmaceutical composition of claim 1 , wherein the composition is characterized by SEC analysis at M 3 or T 2 or T 4 in which: fragment 3 content is less than about 10 wt. %.
6. The stable aqueous pharmaceutical composition of claim 1 , eliciting long term storage stability as characterized by: an HIC analysis at M 3 or T 2 or T 4 wherein the amount of the composition represented by peak 2 of the HIC chromatogram is greater than or equal to about 95 wt. %; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to about 3 wt. %.
7. The stable aqueous pharmaceutical composition of claim 1 , comprising a buffer selected from phosphate, histidine, citrate, maleate, tartrate, succinate, acetate, tris-(hydroxymethyl)-aminomethane (tris), bicarbonate, or a combination thereof.
8. The stable aqueous pharmaceutical composition of claim 1 , comprising a tonicity modifier selected from potassium chloride, sodium citrate, or a combination thereof; and a buffer selected from phosphate, histidine, citrate, maleate, tartrate, succinate, acetate, tris-(hydroxymethyl)-aminomethane (tris), bicarbonate, or a combination thereof.
9. The stable aqueous pharmaceutical composition of claim 1 , comprising a tonicity modifier selected from potassium chloride, sodium citrate, or a combination thereof.
10. The stable aqueous pharmaceutical composition of claim 1 , comprising a tonicity modifier selected from potassium chloride, sodium citrate, or a combination thereof; and a citrate buffer.
11. The stable aqueous pharmaceutical composition of claim 1 , comprising about 10 mM to about 200 mM of a tonicity modifier selected from potassium chloride, sodium citrate, or a combination thereof; and a citrate buffer.
12. A vial, syringe, or injector pen containing the stable aqueous pharmaceutical composition of claim 1 .
13. The vial, syringe or injector pen of claim 12 , comprising about 25 mM NaCl, about 10 mM to about 200 mM of a tonicity modifier selected from potassium chloride, sodium citrate, or a combination thereof; and a citrate buffer.
14. A method of treating a patient in need of treatment with etanercept, comprising administering a therapeutically effective amount of the stable aqueous pharmaceutical composition of claim 1 to said patient.
15. The stable aqueous pharmaceutical composition of claim 1 , wherein the etanercept is 50 mg/mL.
16. The stable aqueous pharmaceutical composition of claim 1 , wherein the sucrose is 1% (w/v).
17. The vial, syringe, or injector pen of claim 12 , wherein the etanercept is 50 mg/mL.
18. The vial, syringe, or injector pen of 12 , wherein the sucrose is 1% (w/v).
19. The method of claim 14 , wherein the etanercept is 50 mg/mL.
20. The method of claim 14 , wherein the sucrose is 1% (w/v).